Ellenhorn, Joshua D.I.

p53-Reactive T Cells Are Associated with Clinical Benefit in Patients with Platinum-Resistant Epithelial Ovarian Cancer After Treatment with a p53 Vaccine and Gemcitabine Chemotherapy

Hardwick, N. R., Frankel, P., Ruel, C., Kilpatrick, J., Tsai, W., Kos, F., Kaltcheva, T., Leong, L., Morgan, R., Chung, V., et al. (2018) · Clinical Cancer Research

Ovarian cancer diagnosis and treatmentImmunotherapy and Immune Responses

Cited by 66

p53MVA Therapy in Patients with Refractory Gastrointestinal Malignancies Elevates p53-Specific CD8+ T-cell Responses

Hardwick, N. R., Carroll, M., Kaltcheva, T., Qian, D., Lim, D., Leong, L., Chu, P., Kim, J., Chao, J., Fakih, M., et al. (2014) · Clinical Cancer Research

Immunotherapy and Immune ResponsesCancer Immunotherapy and Biomarkers

Cited by 45

Overcoming immunosuppression to enhance a p53MVA vaccine

Hardwick, N., Chung, V., Cristea, M., Ellenhorn, J. D., & Diamond, D. J. (2014) · OncoImmunology

Immunotherapy and Immune ResponsesCancer Immunotherapy and Biomarkers

Cited by 11